Welcome to the e-CCO Library!

P382: Comparison of efficacy and safety of biosimilar infliximab to originator infliximab in children with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Muhammed*, L. Whyte, S. Protheroe, R. Bremner, W. Haller, T. Wong

Created: Friday, 22 February 2019, 9:49 AM
P382: CRP/albumin ratio: Predictive factor of the response to corticosteroids in acute severe colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Jardak1*, M. Medhioub2, K. Agar2, L. Hamzaoui1,2,3, A. Khsiba2, M.M. Azouz2

Created: Thursday, 21 February 2019, 9:14 AM
P382: High anti-tumor necrosis factor alpha treatment trough concentrations are not associated with higher rate of adverse events in pediatric patients with inflammatory bowel disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Zvuloni, M.(1);Matar, M.(2);Levi, R.(3);Shamir, R.(1,2);Assa, A.(2,4);
Created: Wednesday, 2 June 2021, 4:12 PM
P382: Serum Ustekinumab Concentrations are Associated with Improved Outcomes with the Magnetic Resonance Index of Activity for Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chen, K.(1,2)*;Chen, J.(3);Smith, E.(1,2);Mathani, P.(1,2);Longman, R.(1,2);Lukin, D.(1,2);Scherl, E.(1,2);Battat, R.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P383 The level of intestinal inflammation and fibrosis in resection specimens after preoperative anti-tumour necrosis factor-α treatment in patients with Crohn’s disease: a comparative pilot study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Torle1, P. Dabir2, U. Korsgaard3, J.J. Christiansen3, N. Qvist4, A. El-Hussuna5

Created: Thursday, 30 January 2020, 10:12 AM
P383: Breast feeding practices differ between mothers with IBD and mothers without IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Baker1, V. Nguyen2, S. Andriasak2, L. Ambrosio3, K.-A. Berga1, L. Dieleman3, B. Halloran3, K.I. Kroeker3, F. Peerani3, K. Wong3, V.W. Huang3*, R.N. Fedorak3

Created: Thursday, 21 February 2019, 9:14 AM
P383: Increasing treatment time on REMICADE® (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in Canada
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Marshall J.K.*1,2, Marrache A.M.3, Ewara E.4

Created: Wednesday, 20 February 2019, 10:36 AM
P383: One-year experience with ustekinumab in therapy-refractory or -intolerant patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Ochsenkühn1, C. Tillack2, F. Schnitzler3, D. Szokodi2, S. Janelidze2

Created: Friday, 22 February 2019, 9:41 AM
P383: Real-life experience of the efficacy, safety and pharmacokinetic data of switching from intravenous to subcutaneous infliximab in inactive inflammatory bowel disease patients. Results from the ENEIDA registry.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Iborra Colomino, M.I.(1)*;Garrido Marín, A.(1);Caballol Oliva, B.(2);Huguet Malavés, J.M.(3);Arias García, L.(4);Mesonero Gismero, F.(5);Fernández Prada, S.J.(6);Boscá Watts, M.M.(7);Ponferrada Díaz, Á.(8);Calvet Calvo, X.(9);Gutiérrez Casbas, A.(10); Ordás Jiménez, I.(2);Ruiz Sanchez, L.(3);Sicilia Aladren, B.(4);Garcia de la Filia, I.(5);Domènech Morral, E.(11);Nos Mateu, P.(1);
Created: Friday, 14 July 2023, 11:05 AM
P383: Relationship between histo-endoscopic mucosal healing and baseline characteristics in patients with moderately to severely active Ulcerative Colitis receiving filgotinib in the phase 2b/3 SELECTION study
Year: 2021
Source: ECCO'21 Virtual
Authors: Peyrin-Biroulet , L.(1);Loftus Jr , E.V.(2);Hibi , T.(3);Birchwood , C.(4);Yun , C.(4);Zhao , S.(4);Liu , X.(4);Rogler , G.(5);Danese , S.(6);Colombel , J.F.(7);Feagan , B.(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P383: Short- and long-term outcomes of infliximab and calcineurin inhibitor treatment for steroid-refractory ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Motoya*, M. Miyakawa, M. Nasuno, H. Tanaka

Created: Friday, 22 February 2019, 9:49 AM
P383: Ustekinumab as an opportunity for refractory Ulcerative Colitis patients.
Year: 2022
Source: ECCO'22
Authors: Iborra, M.(1);Soutullo, C.(1);Gimeno, M.(1);Bastida, G.(1);Aguas, M.(1);Cerrillo, E.(1);Sáez-González, E.(1);Garrido, A.(1);Mínguez, A.(1);Bordetas, J.(1);Nos, P.(1);
Created: Friday, 11 February 2022, 3:52 PM
P384 Lower infliximab trough levels are associated with higher bowel wall thickness in Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Frias Gomes1, B. Morão1, C. Neto Nascimento1, C. Gouveia1, C. Palmela1, J. Strecht2, J. Torres1

Created: Thursday, 30 January 2020, 10:12 AM
P384: A higher red blood cell methotrexate polyglutamate 3 concentration is associated with methotrexate drug-survival in patients with Crohn's Disease: first results of a prospective cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Van De Meeberg, M.(1)*;Fidder, H.(2);Sundaresan, J.(3);Struys, E.(3);Oldenburg, B.(2);Mares, W.(4);Mahmmod, N.(5);van Asseldonk, D.(6);Lutgens, M.(7);Kuyvenhoven, J.(8);Rietdijk, S.(9);Nissen, L.(10);Koehestanie, P.(11);de Jonge, R.(3);Bulatović Ćalasan, M.(12);Bouma, G.(13);
Created: Friday, 14 July 2023, 11:05 AM
P384: Gari-leo prospective study on anti-TNF therapy in ulcerative colitis relapse patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Kato*, K. Kani, A. Ishibashi, M. Oka, S. Nagoshi, K. Yakabi

Created: Thursday, 21 February 2019, 9:14 AM
P384: High incidence of hyperglycaemia in steroid treated hospitalised inflammatory bowel disease (IBD) patients and its risk factors identified by machine learning methods
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. McDonnell*1, R. Harris1, T. Mills1, L. Downey1, S. Dharmasiri1, R. Felwick1, F. Borca2, H. Phan2, F. Cummings1,3, M. Gwiggner1

Created: Friday, 22 February 2019, 9:41 AM
P384: Long-term outcome and endoscopic healing rates following long modified side-to-side strictureplasties
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Van Stappen J.*1, De Buck van Overstraeten A.2, Ferrante M.1, Vanbeckevoort D.3, Van Assche G.1, D'Hoore A.2, Vermeire S.1

Created: Wednesday, 20 February 2019, 10:36 AM
P384: Postoperative Endoscopic Recurrence In Patients With Crohn’s Disease After “Curative” Ileocecal Resection on Prophylaxis Treatment With Either Anti-TNFs, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study
Year: 2022
Source: ECCO'22
Authors: Yanai, H.(1,2);Amir Barak , H.(1,2);Kagramanova, A.(3);Knyazev , O.(3);Sabino, J.(4);Haenen, S.(4);Mantzaris , G.J.(5);Mountaki, K.(5);Pugliese, D.(6);Armuzzi, A.(6,7);Furfaro, F.(8);Fiorino, G.(8);Drobne, D.(9,10);Kurent, T.(10);Yassin, S.(2,11);Maharshak, N.(2,11);Castiglione, F.(12);Nardone, O.M.(12);de Sire, R.(12);Farkas, K.(13);Molnar, T.(13);Krznaric, Z.(14);Brinar, M.(14);Chashkova, E.(15);Margolin, M.L.(2,16);Kopylov, U.(2,16);Bezzio, C.(17);Bar-Gil Shitrit, A.(18);Lukas , M.(19,20);Chaparro, M.(21);Truyens, M.(22,23);Nancey, S.(24);Revés, J.(25);Avni-Biron, I.(1,2);Ollech, J.E.(1,2);Dotan, I.(1,2);Aharoni Golan, M.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P384: The usefulness of salazosulfapyridine for 
patients with ulcerative colitis refractory to mesalazine
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Yoshino*, S. Yazumi

Created: Friday, 22 February 2019, 9:49 AM